SCHEMBL4833277

SCHEMBL4833277

COc1cc2c(cc1OC)C(CCN1CCC(O)(c3ccc(Cl)cc3)CC1)N(C(=O)C1CCCCCC1)CC2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 6/20 0.61
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
NR1I2 O75469 1/20 0.47
MAOA P21397 1/20 0.47
PTGS2 P35354 1/20 0.47
OPRK1 P41145 1/20 0.47
SLC6A3 Q01959 1/20 0.47
GRIN2C Q14957 5/20 0.46
TRPV1 Q8NER1 1/20 0.45
DRD2 P14416 2/20 0.44
DRD1 P21728 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838194 0.88 MTNR1B (0.53) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4833288 0.81 NR1I2 (0.47) MTNR1BTSHRMAPK1NR1I2MAOA
SCHEMBL4839658 0.80 MTNR1B (0.63) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4839308 0.80 MTNR1B (0.62) MTNR1BALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL4841461 0.78 MTNR1B (0.60) MTNR1BMEN1KMT2AALDH1A1CYP1A2
SCHEMBL4839235 0.77 MTNR1B (0.55) MTNR1BMEN1KMT2AALDH1A1CYP1A2
SCHEMBL4832883 0.76 OPRM1 (0.48) MTNR1BOPRK1SLC6A3DRD2DRD1
SCHEMBL4839599 0.74 OPRM1 (0.48) MTNR1BOPRK1SLC6A3DRD2DRD1
SCHEMBL4841433 0.74 MTNR1B (0.54) MTNR1BMEN1KMT2AALDH1A1CYP1A2
SCHEMBL4841428 0.73 MTNR1B (0.53) MTNR1BMEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 MTNR1B 621/4885MEN1 1680/4885KMT2A 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.